Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Lepu Biopharma Co. Ltd. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners, resulting in a one-to-one ratio of examiners to pending matters. The prosecution involves 2 distinct art units, indicating that the applications are grouped into two separate technical divisions at the USPTO.
The busiest examiner for this portfolio is DEBERRY, REGINA M, who handles 1 pending office action. Because each of the 5 distinct examiners is responsible for exactly 1 pending action, the company's prosecution is entirely decentralized at the individual level. This distribution means that the company must navigate five different sets of examiner preferences across the 5 pending office actions.
With 2 distinct art units overseeing the 5 pending actions, there is some administrative consolidation despite the variety of examiners. Practitioners should look for consistency in how these 2 art units handle Biotechnology & Pharmaceuticals cases. The decentralized nature of the 5 distinct examiners suggests that the company is receiving a broad spectrum of feedback from the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18454015 | ANTI-CD47 ANTIBODIES AND USES THEREOF | HADDAD, MAHER M | 10d overdue |
| 18700235 | ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS | DEBERRY, REGINA M | — |
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| 18582571 | TUMOR ANTIGEN-DEPENDENT CD40 AGONISTS ANTIBODIES | REDDIG, PETER J | — |
| 17997775 | ANTIBODY-DRUG CONJUGATE AND PREPARATION THEREOF | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700235 | ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS | DEBERRY, REGINA M | — | §112 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — | §102§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18582571 | TUMOR ANTIGEN-DEPENDENT CD40 AGONISTS ANTIBODIES | REDDIG, PETER J | — | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18454015 | ANTI-CD47 ANTIBODIES AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | 10d overdue | Pending | Aug 22, 2023 |
| 17997775 | ANTIBODY-DRUG CONJUGATE AND PREPARATION THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial